Published in Biochem J on August 15, 2007
Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol (2012) 1.44
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 1.00
High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol (2009) 0.93
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro Oncol (2010) 0.91
Insulin-like growth factor system and sporadic malignant melanoma. Am J Pathol (2010) 0.91
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One (2012) 0.88
Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer (2014) 0.86
Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One (2014) 0.85
Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice. PLoS One (2010) 0.83
Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int (2011) 0.80
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Neuro Oncol (2015) 0.80
The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. Oncotarget (2016) 0.75
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res (2015) 0.75
The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. Neuro Oncol (2017) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54
Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem (2001) 8.47
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55
Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J (1996) 6.36
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev (1996) 6.01
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem (1992) 5.64
IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J (1993) 5.46
The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer (2004) 4.59
Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci (1997) 4.52
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell (2004) 4.29
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res (1999) 4.26
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem (2001) 3.78
Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature (2006) 3.71
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 3.50
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci U S A (2000) 2.91
Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol (2001) 2.76
Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol (2003) 2.63
Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol (2004) 2.53
Central insulin action in energy and glucose homeostasis. J Clin Invest (2006) 2.51
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35
Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol (2004) 2.33
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol (2005) 2.19
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol (2002) 2.15
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A (2005) 1.96
Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res (2002) 1.81
Molecular interactions of the IGF system. Cytokine Growth Factor Rev (2005) 1.75
Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol (2005) 1.73
Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene (1999) 1.66
Targeting insulin-like growth factor pathways. Br J Cancer (2006) 1.57
Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level. Biochem J (1990) 1.41
Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol Cell Biol (2006) 1.30
Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res (2005) 1.27
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene (2003) 1.23
Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci U S A (1997) 1.19
Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res (2000) 1.15
The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res (2004) 1.12
Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene (2006) 1.01
Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol (2005) 1.00
Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer (2007) 0.98
Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene (2006) 0.97
IGF-IR: potential role in antitumor agents. Drug News Perspect (2006) 0.95
Autocrine regulation of insulin secretion in human ejaculated spermatozoa. Endocrinology (2004) 0.95
Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res (2004) 0.92
Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep (2006) 0.90
Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67. Mod Pathol (1999) 0.85
Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol (2001) 0.83
Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer (2006) 0.82
Apoptotic response of malignant rhabdoid tumor cells. Cancer Cell Int (2003) 0.81
Differential role of insulin receptor autophosphorylation sites 1162 and 1163 in the long-term insulin stimulation of glucose transport, glycogenesis, and protein synthesis. J Biol Chem (1992) 0.80
Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene (2006) 0.80
Rat fibroblast cells overexpressing kinase-inactive human insulin receptors are insulin responsive: influence of growth conditions. Endocrinology (1995) 0.76
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol (2010) 4.93
A high-resolution anatomical atlas of the transcriptome in the mouse embryo. PLoS Biol (2011) 4.84
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Protein interaction mapping: a Drosophila case study. Genome Res (2005) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med (2009) 3.57
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Mesenchymal stem cell features of Ewing tumors. Cancer Cell (2007) 3.04
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics (2011) 2.86
Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. Bioinformatics (2010) 2.79
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data. Bioinformatics (2010) 2.63
Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46
A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet (2012) 2.45
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood (2005) 2.35
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol (2012) 2.29
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol (2009) 2.15
Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol (2009) 2.04
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet (2004) 1.98
Background ionizing radiation and the risk of childhood cancer: a census-based nationwide cohort study. Environ Health Perspect (2015) 1.88
VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics (2006) 1.87
Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood (2008) 1.82
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res (2012) 1.78
High shear-dependent loss of membrane integrity and defective platelet adhesion following disruption of the GPIbα-filamin interaction. Blood (2010) 1.75
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J (2007) 1.74
Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood (2009) 1.74
MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 1.73
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer (2008) 1.72
High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol (2012) 1.71
Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet (2013) 1.69
Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood (2012) 1.67
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer (2008) 1.66
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood (2006) 1.63
The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One (2009) 1.63
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res (2009) 1.61
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell (2007) 1.56
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood (2011) 1.56
Germline gain-of-function mutations of ALK disrupt central nervous system development. Hum Mutat (2011) 1.54
Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol (2007) 1.52
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.50
A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene (2002) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci U S A (2008) 1.43
Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood (2002) 1.42
Intercellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol (2003) 1.42
Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation (2009) 1.40
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res (2008) 1.39
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci (2002) 1.38
Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov (2003) 1.37
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood (2006) 1.37
Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol (2010) 1.36
The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program (2011) 1.34
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol (2007) 1.31
Interaction between platelet glycoprotein Ibalpha and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear. J Biol Chem (2001) 1.30
Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res (2008) 1.30
De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis. Nucleic Acids Res (2010) 1.30
SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol (2014) 1.27
Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol (2005) 1.26
Extra-renal non-cerebral rhabdoid tumours. Pediatr Blood Cancer (2008) 1.26
SHIP1 and Lyn Kinase Negatively Regulate Integrin alpha IIb beta 3 signaling in platelets. J Biol Chem (2004) 1.25
Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA. J Biol Chem (2003) 1.24
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res (2011) 1.24
Distinct glycoprotein Ib/V/IX and integrin alpha IIbbeta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem (2001) 1.23
Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol (2003) 1.23
Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci (2009) 1.22
Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood (2006) 1.21
DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum Mol Genet (2009) 1.19
Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res (2007) 1.18
Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol (2004) 1.18
A microfluidics device to monitor platelet aggregation dynamics in response to strain rate micro-gradients in flowing blood. Lab Chip (2009) 1.16
Procoagulant platelets: are they necrotic? Blood (2010) 1.15
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res (2010) 1.15
Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol (2011) 1.15
Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol (2013) 1.14